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Abstract: Maternal obesity increases fetal adiposity which may adversely affect metabolic health
of the offspring. Choline regulates lipid metabolism and thus may influence adiposity. This study
investigates the effect of maternal choline supplementation on fetal adiposity in a mouse model
of maternal obesity. C57BL/6J mice were fed either a high-fat (HF) diet or a control (NF) diet
and received either 25 mM choline supplemented (CS) or control untreated (CO) drinking water
for 6 weeks before timed-mating and throughout gestation. At embryonic day 17.5, HF feeding
led to higher (p < 0.05) percent total body fat in fetuses from the HFCO group, while the choline
supplemented HFCS group did not show significant difference versus the NFCO group. Similarly,
HF feeding led to higher (p < 0.05) hepatic triglyceride accumulation in the HFCO but not the
HFCS fetuses. mRNA levels of lipogenic genes such as Acc1, Fads1, and Elovl5, as well as the
transcription factor Srebp1c that favors lipogenesis were downregulated (p < 0.05) by maternal choline
supplementation in the HFCS group, which may serve as a mechanism to reduce fat accumulation in
the fetal liver during maternal HF feeding. In summary, maternal choline supplementation improves
indices of fetal adiposity in obese dams at late gestation.
Keywords: choline; fetal adiposity; gestation; obesity; lipogenesis

1. Introduction
Maternal obesity is a major public health problem which increases the risk of pregnancy
complications [1], such as gestational diabetes mellitus (GDM) characterized by hyperglycemia and
glucose intolerance, and adverse fetal growth outcomes, such as macrosomia, defined as a birthweight
of more than 4 kg [2,3]. Macrosomia at birth has been demonstrated to correlate with higher incidences
of adolescent obesity and cardio-metabolic disease later in life [4–6].
Moreover, macrosomia resulting from maternal obesity often displays a sheer increase in fat mass
without a proportional change in lean tissue mass [7,8]. The rise in fetal adiposity is attributed to both
increased de novo lipogenesis and maternal transport of fatty acids to the fetus [9]. Maintaining the
homeostasis of lipid metabolism and transport of the maternal-fetal dyad may be an effective approach
to prevent macrosomia arising from maternal obesity [10].
Nutrients 2017, 9, 899; doi:10.3390/nu9080899
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Choline is an essential nutrient which participates in various biochemical pathways in
the body. Derivatives of choline, e.g., acetylcholine, betaine, and phosphatidylcholine (PC),
serve as a neurotransmitter, a methyl donor, and an essential component of cellular and
lipoprotein membranes, respectively [11]. Choline deficiency in both humans and rodents results
in fatty liver and liver cell damage [12,13]. Choline possibly influences hepatic and whole
body lipid metabolism in a multi-faceted manner. Since PC is a component of lipoproteins,
its deficiency impairs the secretion of lipoproteins, such as very low density lipoproteins
(VLDLs) from the liver, and results in lipid accumulation in the liver [14]. A specific
form of PC, 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine, is a ligand for the peroxisome
proliferator-activated receptor alpha (PPARα), which promotes fatty acid catabolism via
β-oxidation [15]. Another PC species, dilauroyl-PC, is an agonist of liver receptor homolog 1 (LRH-1),
which activates bile acid synthesis [16]. Additionally, intracellular PC synthesis is critical for inhibiting
the maturation and activation of sterol regulatory element-binding protein 1 (SREBP1), a transcription
factor that promotes lipogenesis [17]. SREBP1 isoform c (SREBP-1c) activates many lipogenic genes
including acetyl-CoA carboxylases (ACCs) which convert acetyl-CoA to malonyl-CoA [18], fatty acid
synthase (FASN) which uses acetyl-CoA and malonyl-CoA to synthesize fatty acids [19], stearoyl-CoA
desaturase-1 (SCD1) and fatty acid desaturases (FADSs) which mediate the formation of unsaturated
fatty acids [20], and fatty acid elongase 5 (ELOVL5) which elongates polyunsaturated fatty acids [21].
In summary, choline plays a critical role in enhancing lipid export from the liver, promoting fatty acid
catabolism, and reducing lipogenesis. Therefore, maternal choline status may affect circulating lipids
supplied to the placenta and eventually acquired by the fetus, whereas choline status in the fetus may
influence fetal lipid metabolism directly via the aforementioned mechanisms.
Choline can be oxidized to betaine and serve as a methyl donor for methylation reactions
including DNA and histone methylation, thereby modifying the epigenetic marks. Supplementation
of different methyl donors (e.g., folate, betaine, choline) consistently alleviates steatosis, suggesting
the importance of methylation for lipid metabolism [22–24]. An obesogenic diet was shown to alter
the DNA methylation profile of FASN in rats [22]. Several other genes related to lipid metabolism,
such as PPAR-γ and the LDL receptor, were also reported to be epigenetically regulated via DNA
and/or histone methylation [25,26]. Moreover, maternal HF feeding elicited epigenetic alterations
in an array of genes related to steatohepatitis in rats [27], while another study demonstrated that
maternal folic acid supplementation determined lipid metabolism by altering PPAR expression in rat
progeny [28]. As a methyl donor, choline may modify the epigenetic influence of maternal HF feeding
on fetal lipid metabolism.
In this study, we examined the effect of maternal choline supplementation on fetal growth and
adiposity at late gestation (i.e., embryonic day E17.5) in HF feeding-induced obese dams.
2. Materials and Methods
2.1. Animals and Diets
Six-week-old C57BL/6J mice were purchased from Jackson Laboratories. The mice were kept at a
temperature of 22 ◦ C, humidity 40%–60%, and a 12-hour/12-hour light/dark cycle. Regular bedding
and enrichment were provided in the cages. Female mice were divided into groups receiving either
a high fat diet (HF) or a normal fat control diet (NF). The HF diet contained 60% kcal fat (Research
Diets D12492, Research Diets, New Brunswick, NJ, USA) and the NF diet contained 10% kcal fat
(Research Diets D12450J). The animals either received 25 mM choline chloride in water (CS) or control
untreated drinking water (CO) throughout the study period. Based on the different diets and choline
supplementation, the four experimental groups were: NFCO (normal fat, untreated water), NFCS
(normal fat, choline supplemented water), HFCO (high fat, untreated water), and HFCS (high fat,
choline supplemented water) (Figure 1). Male mice for mating followed the NFCO diet and fluid
assignment. All animals had free access to food and water. Composition of experimental diets was
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analytical scale. Thereafter, the fetal carcasses were dissected to retrieve whole liver and brain samples.
The livers, brains, and fetal carcasses were immersed in RNAlater® (Thermo Scientific, Grand Island,
NY, USA) for overnight stabilization or snap frozen in liquid nitrogen before being stored at −80 ◦ C.
The study protocol was approved by the Institutional Animal Care and Use Committee (IACUC) at
Brooklyn College. The animal study approval number is 274.
2.4. Analytical Measurements
For analytical measurement of placental samples, we excluded dams with a litter size lower than
5 or higher than 10 to prevent the potential confounding effect of litter size on metabolic parameters.
Two samples were randomly selected from each litter unless specified otherwise. Litter size or breeding
success rate was not affected by group assignment (data not shown).
2.4.1. Embryo Sexing
Sex of all fetuses was determined by PCR of a sequence specific to the mouse sex-determining
region Y (Sry) gene on the Y chromosome [33].
2.4.2. Fetal Adiposity Assessment
Total fat of fetuses was extracted using the Folch method [34]. Briefly, carcasses (without liver and
brain) were pulverized in liquid nitrogen. A portion of about 50 mg of the carcass was weighed with
an analytical balance and immersed in 0.9% sodium chloride. The samples were homogenized with a
homogenizer. Thereafter, 800 µL of chloroform: methanol (2:1) was added to the samples and mixed
thoroughly on a shaker for one hour. The mixture was centrifuged at 5000× g for 10 min after which
the lower layer of liquid was transferred to a pre-weighed microcentrifuge tube and dried using a
vacuum dryer. After the sample was completely dried in the pre-weighed tube, it was again weighed.
The difference between two weight measurements was the weight of fat extracted from the sample.
Percent total fat was calculated as fat weight/carcass sample weight × 100%.
2.4.3. Serum Insulin, Glucose, Triglyceride, and Free Fatty Acid (FFA) Measurements
Maternal serum biomarkers were measured with assay kits according to the manufacturers’
instructions: insulin was measured with the Mouse Insulin ELISA kit (ALPCO, Salem, NH, USA);
glucose and triglycerides were measured with the glucose and triglyceride colorimetric assay kits
(Cayman, Ann Arbor, MI, USA); FFAs were measured with the HR Series NEFA-HR(2) colorimetric
reagents (Wako Diagnostics, Richmond, VA, USA).
2.4.4. Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) Index
The HOMA-IR index is an assessment of insulin resistance. It was calculated as [fasting serum
glucose (mmol/L) × fasting serum insulin (pmol/L)/22.5].
2.4.5. Choline Measurements
Whole fetal livers were used for choline extraction and quantification. Measurements of choline
and its derivatives were conducted using LC-MS/MS methodology [35]. The liver of one fetus from
each dam was randomly chosen for the measurement.
2.4.6. RNA Extraction and Quantitative Real-Time PCR
RNA was extracted from fetal livers using the TRIzol®reagent (Thermo Fisher Scientific,
Waltham, MA, USA). Reverse transcription was conducted using the High-Capacity cDNA Reverse
Transcription kit (Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer’s
instructions. Gene transcript abundance was analyzed by quantitative real-time PCR with SYBR
green detection using the CFX384 Touch™ Real-Time PCR Detection System (Bio-Rad, Hercules,
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CA, USA). The reaction conditions were as follows: 95 ◦ C for 3 min, followed by 39 cycles with
20 s at 95 ◦ C, 30 s at 58 ◦ C, and 20 s at 72 ◦ C. Data were normalized as the fold difference of the
gene of interest relative to the housekeeping gene beta-actin (Actb) and analyzed using the ∆∆Ct
method [36]. Primers were either designed using GeneRunner Version 3.01 (http://www.softpedia.
com) (Table S1) or previously published [37]. Expression of the following genes was analyzed: Acc1,
Acc2, peroxisomal acyl-coenzyme A oxidase 1 (Acox1), betaine-homocysteine S-methyltransferase 1
(Bhmt1), choline dehydrogenase (Chdh), carbohydrate-responsive element-binding protein (Chrebp1),
diacylglycerol O-acyltransferase 1 (Dgat1), Elovl5, Fads1, Fasn, fatty acid transport protein 1 (Fapt1),
microsomal triglyceride transfer protein (Mttp), choline-phosphate cytidylyltransferase A (Pcyt1a),
phosphatidylethanolamine N-methyltransferase (Pemt), and Scd1.
2.4.7. Maternal and Fetal Liver Triglyceride Measurements
Whole maternal livers were pulverized in liquid nitrogen. Thereafter, 50 mg of the pulverized
tissue was used for triglyceride quantification using the Triglyceride Colorimetric Assay Kit
(Cayman) according to the manufacturer’s instructions. Whole fetal livers were used for triglyceride
concentration quantification using the same method.
2.4.8. Statistical Analyses
General linear models (GLMs) were constructed to assess the differences in the dependent
variables (e.g., embryonic weight and gene expression) with diet (D: HF or NF), supplementation
(S: CO or CS), and their interaction (D × S) as independent variables. GTT curves were analyzed with
GLM Repeated Measure. Posteriori analyses were conducted to detect differences among the groups
using one-way analysis of variance (ANOVA) followed by post-hoc Fisher's least significant difference
(LSD) tests if there was a D × S interaction. Considering that the small sample size may limit the
statistical power to detect a true interaction, pD×S ≤ 0.2 was used to identify suggestive evidence for
the presence or absence of interaction. This method was successfully used in other studies [38,39].
For the dependent variables that included measurements of multiple embryos from the same dam
(e.g., embryonic weight, body fat), we first used GLMs to assess the effect of embryonic sex adjusted
for D and S. Since no sexual dimorphism was detected, we calculated the averages of each dam and
use the pooled data from each dam for GLM and posteriori ANOVA analyses. Litter size was also
included in the model as an independent variable if it significantly modified the dependent variable.
Dependent variables deviating from the normal distribution were logarithmically transformed before
analysis. A p value < 0.05 was considered as significant. Values are presented as means ± standard
error of mean (SEM).
3. Results
3.1. Food and Choline Intake
The weight of food pellets consumed each week was lower (pD < 0.01) in the HF groups than in
the NF groups (Table 1). However, since the HF diet had a higher calorie density than the normal
diet, the HF groups still had higher (pD < 0.01) caloric intake per week than the NF groups. There
was a D × S interaction for water consumption (pD×S = 0.02). However, posteriori analysis did not
reveal significant difference among the groups (p = 0.1). Total choline intake from food and water
was on average 4.5 times higher in the choline supplemented groups versus the control groups. Total
choline intake from food and water was not significantly different between the HFCS and NFCS
groups. The HFCO group had about 21% higher (p < 0.01) weekly choline consumption from food
than the NFCO group. However, the amount of additional choline from food was relatively small
compared to the supplemental dose from water, and was not likely to confound the effect of choline
supplementation on the NF and HF dams.
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Table 1. Average weekly food and choline intake of dams 1 .

Food and Choline Intake
Food and Choline Intake

Table
weekly foodHFCO
and choline intake
of dams 1 p Value
NFCO1. Average
NFCS
HFCS
(n = 10)

Food intake (g/week)
17.4 ± 0.2
intake (g/week)
Caloric intake Food
(kcal/week)
67 ± 1
Caloric intake (kcal/week)
Water intake (mL/week)
20.2 ± 0.4 a
(mL/week)
Choline intakeWater
from intake
food (µmol/week)
132 ± 2
intake(µmol/week)
from food (μmol/week)
Choline intakeCholine
from water
N/A
Choline
intake from water (μmol/week)
Total choline intake
(µmol/week)
132 ± 2 a
1

3.2.

Total choline intake (μmol/week)

(n = 6)
NFCO

(n = 8)
NFCS

HFCO(n = 7) HFCS D

(n17.4
= 10)± 0.3 (n =15.5
6) + 0.3 (n = 8)14.9 ± 0.3
(n = 7) <0.01
17.4
17.481
± 0.3
0.3± 1 14.9 ± 0.3
66 ±±0.2
2
± 1 15.5 +78
<0.01
a ± 120.2 ± 0.5
6721.7
± 1 ± 0.8 a 66 ±21.2
2 ± 0.4 81
78 a± 1 0.6
a
a
a
a
21.7160
± 0.8
0.4 ± 3 20.2 ± 0.5
20.2
0.44
<0.01
133± ±
± 3 21.2 ±155
133
±
4
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±
3
155
±
3
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2
542 ± 16
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501 ± 13
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± 16
c ± 130.4
663 ± 12 c 542160
± 12501
± 3 b N/A 664
663 ± 12 c
160 ± 3 b
664 ± 12 c
132 ± 2 a

pSValue D × S
D
0.3
<0.01
0.3
<0.01
0.7
0.6
0.5
<0.01
N/A
0.08
0.01
0.4

S
0.4
0.3
0.3
0.3
0.02
0.7
0.4
0.5
N/A
N/A
0.1
0.01

D×S
0.4
0.3
0.02
0.4
N/A
0.1

Experimental diets
were fed to dams
fromfed
6 weeks
before
gestational day
17.5. n is the
1 Experimental
diets were
to dams
fromtimed-mating
6 weeks beforetotimed-mating
to gestational
daynumber
17.5. n is
of dams. Data were analyzed using the general linear model. Posteriori analysis of variance (ANOVA) followed
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by maternal choline supplementation (Figure 2b).
not modified by maternal choline supplementation (Figure 2b).

Figure 2. Weight gain and intraperitoneal glucose tolerance (IGT) of dams fed experimental diets.
Figure 2. Weight gain and intraperitoneal glucose tolerance (IGT) of dams fed experimental diets. (a)
(a) Weight gain was
measured both before timed-mating and during gestation (E0.5–E17.5); (b) Visceral
Weight gain was measured both before timed-mating and during gestation (E0.5–E17.5); (b) Visceral
fat was measured
at
(c) IGT
tests
conducted
at E15.5
withwith
2 g/kg
injected;
fat wasE17.5;
measured
at E17.5;
(c)were
IGT tests
were conducted
at E15.5
2 g/kgD-glucose
D-glucose injected;
(d)
(d) The area under
the
curve
(AUC)
of
the
IGT
tests.
NFCO
(solid
bars):
n
=
10;
NFCS
(shaded
bars):
The area under the curve (AUC) of the IGT tests. NFCO (solid bars): n = 10; NFCS (shaded bars):
n=
6; HFCO
(open
n = 8;(hatched
HFCS (hatched
7. Datawere
wereanalyzed
analyzed using
thethe
general
linear
n = 6; HFCO (open
bars):
n = bars):
8; HFCS
bars):bars):
n = n7.= Data
using
general
linear model. Posteriori analysis of variance (ANOVA) followed by posthoc Fisher's least significant
difference (LSD) analysis between groups was conducted with pD×S ≤ 0.2. Values are mean ± standard
error of mean (SEM); different letters indicate p < 0.05 in the posthoc analysis. ns: pD , pS , and pD×S ,
not significant. CO: control; CS: choline supplemented; D: diet; HF: high-fat diet; NF: normal-fat diet;
S: supplementation.
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HF feeding led to impaired glucose tolerance of pregnant mice at E15.5 (HF versus NF groups,
pD < 0.01) (Figure 2c,d), suggesting that blood glucose disturbances, typically observed in GDM, were
maintained into late gestation. Interestingly, choline supplementation improved glucose tolerance
of the dams (pS < 0.01). Maternal HF feeding tended to interact with choline supplementation to
affect insulin secretion (pD×S = 0.1). Posteriori analysis suggested that maternal serum insulin levels
were higher in the NFCS than the other groups (p = 0.02) (Table 2), suggestive of hyperinsulinemia
that is often associated with insulin resistance. However, neither the fasting serum glucose nor the
HOMA-IR index was significantly affected by maternal HF or CS. Collectively, the NFCS dams may
have differential regulation of insulin secretion or blood glucose uptake at E17.5, but the mechanism
and the combined effect of different factors on their blood glucose control are unclear. Choline
supplementation led to higher (ps = 0.02) serum triglyceride concentrations and tended to increase
(ps = 0.06) serum FFA levels versus the control (NFCO and HFCO) groups, which could be related
to increased fat export from the liver. Indeed, choline supplementation significantly reduced liver
triglyceride levels (ps < 0.01). In summary, maternal biomarkers did not seem to be consistently
improved by choline supplementation.
Table 2. Maternal serum and liver biomarkers at gestational day 17.5 1 .
Maternal Biomarkers
Serum insulin (ng/mL)
Serum glucose (mg/dL)
HOMA-IR index
Serum triglycerides (mg/dL)
Serum FFAs (mmol/L)
Liver triglycerides (mg/g tissue)

NFCO

NFCS

HFCO

HFCS

p Value

(n = 8)

(n = 6)

(n = 8)

(n = 7)

D

S

D×S

0.63 ± 0.05 a
103.5 ± 5.9
28.0 ± 2.9
37.9 ± 3.5
0.52± 0.12
17.8 ± 4.9 a

0.81± 0.06 b
88.9± 6.9
30.3 ± 3.4
46.6 ± 5.2
0.74 ± 0.2
9.3 ± 6.4 a

0.57 ± 0.05 a
103.7 ± 5.9
24.9 ± 2.9
31.2 ± 3.7
0.64 ± 0.14
37.3 ± 5.5 b

0.57 ± 0.05 a
94.1 ± 6.4
23.2 ± 3.1
50.6 ± 4.1
0.80 ± 0.16
13.9 ± 5.5 a

0.01
0.7
0.1
0.7
0.9
0.04

0.08
0.07
0.9
<0.01
0.06
<0.01

0.1
0.7
0.5
0.5
0.4
0.2

1

Experimental diets were fed to dams from 6 weeks before timed-mating to gestational day 17.5. n is the number
of dams. Data were analyzed using the general linear model. Posteriori analysis of variance (ANOVA) followed
by posthoc Fisher’s least significant difference (LSD) analysis between groups was conducted with pD×S ≤ 0.2.
Different letters: a and b, indicate p < 0.05 in the posthoc analysis; Values represent means ± standard error of
mean (SEM). FFA: free fatty acid; HOMA-IR: homeostasis model assessment of insulin resistance = fasting insulin
concentration (pmol/L) × fasting glucose concentration (mmol/L)/22.5. CO: control; CS: choline supplemented;
D: diet; HF: high-fat diet; NF: normal diet; S: supplementation.

3.3. Placental and Embryonic Outcomes
3.3.1. Maternal Choline Supplementation during HF Feeding Did Not Affect Fetal Weight but
Reduced Fetal Adiposity
At E17.5, fetal weight was not significantly different among the groups (Figure 3a). Despite the
lack of difference in body weight, maternal HF feeding and choline supplementation tended to interact
to affect percent body fat (pD×S = 0.08) and hepatic triglyceride content (pD×S = 0.06) of the fetuses.
Posteriori analysis suggested that percent body fat of the fetus was higher in the HFCO group (HFCO
versus NFCO, p = 0.03), whereas the HFCS group had similar percent body fat to NFCO (Figure 3b).
Moreover, the HFCO group also had higher hepatic triglyceride content (p = 0.02), whereas that of the
HFCS group was not significantly different from the NFCO group (Figure 3c). These results suggested
that maternal choline supplementation partially prevented excess adiposity of fetuses from the HF-fed
dams at E17.5.
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(c) fetal liver triglyceride concentrations. Experimental diets were fed to dams from 6 weeks before
fetal liver triglyceride concentrations. Experimental diets were fed to dams from 6 weeks before
timed-mating to gestational day 17.5. Data were analyzed using the general linear model. Posteriori
timed-mating to gestational day 17.5. Data were analyzed using the general linear model. Posteriori
analysis of variance (ANOVA) followed by posthoc Fisher's least significant difference (LSD) analysis
analysis of variance (ANOVA) followed by posthoc Fisher's least significant difference (LSD)
between groups was conducted with pD×S ≤ 0.2. NFCO (solid bars): n = 9; NFCS (shaded bars): n = 6;
analysis between groups was conducted with pD×S ≤ 0.2. NFCO (solid bars): n = 9; NFCS (shaded bars):
HFCO (open bars): n = 7; HFCS (hatched bars): n = 6. n is the number of dams. Fetal weight was
n = 6; HFCO (open bars): n = 7; HFCS (hatched bars): n = 6. n is the number of dams. Fetal weight was
analyzed with pooled data of all fetuses in each dam (5–10/dam); body fat and liver triglyceride
analyzed with pooled data of all fetuses in each dam (5–10/dam); body fat and liver triglyceride
concentrations were analyzed with pooled data of two randomly selected fetuses in each dam. Values
were
analyzed
pooled
data
of twop <
randomly
inns:
each dam.
are mean concentrations
± standard error
of mean
(SEM);with
different
letters
indicate
0.05 in theselected
posthocfetuses
analysis.
Values
are
mean
±
standard
error
of
mean
(SEM);
different
letters
indicate
p
<
0.05
in
the
pD , pS , and pD×S , not significant. CO: control; CS: choline supplemented; D: diet; HF: high-fat diet; NF: posthoc
analysis.
ns: pD, pS, and pD×S, not significant. CO: control; CS: choline supplemented; D: diet; HF:
normal-fat
diet; S: supplementation.
high-fat diet; NF: normal-fat diet; S: supplementation.

3.3.2. Maternal Choline Supplementation during HF Feeding Downregulated Lipogenic Gene
3.3.2.
Choline Supplementation during HF Feeding Downregulated Lipogenic Gene
Expression
in Maternal
Fetal Livers
Expression in Fetal Livers
We next examined the mRNA abundance of a series of genes related to lipid metabolism in the
We next
thedecreased
mRNA abundance
of a series of
related
to lipid
in the
fetal liver (Figure
4a).examined
HF feeding
mRNA abundance
of genes
Fasn (HF
versus
NF, pmetabolism
D < 0.01),
fetalthat
livermediates
(Figure 4a).
feeding decreased
mRNA
abundance
of Fasn
NF,
pD < 0.01), an
an enzyme
the HF
production
of fatty acids
from
acetyl-CoA,
Acc2(HF
(pDversus
= 0.05)
which
enzyme
that
mediates
the
production
of
fatty
acids
from
acetyl-CoA,
Acc2
(p
D = 0.05) which also
also mediates fatty acid synthesis, and Scd1 (pD = 0.05), a rate-limiting enzyme in the formation of
mediates fatty
acid synthesis,
and Scd1
(pD = 0.05), a rate-limiting
enzyme
the formation of
monounsaturated
fatty acids.
Maternal choline
supplementation
decreased Fads1
whichin
is involved
monounsaturated
acids.by
Maternal
choline
is involved
with unsaturated
fatty acidfatty
synthesis
mediating
fattysupplementation
acid desaturationdecreased
(CS versusFads1
CO, which
pS = 0.02).
with
unsaturated
fatty
acid
synthesis
by
mediating
fatty
acid
desaturation
(CS
versus
CO,
Maternal HF feeding and choline supplementation tended to interact to affect the expression of Acc1pS = 0.02).
Maternal HF
feeding
and
choline and
supplementation
tendedunsaturated
to interact tofatty
affect
theelongation.
expression of Acc1
which participates
in fatty
acid
synthesis
Elovl5 which affects
acid
which
participates
in fatty
acid synthesis
and
Elovl5
which
unsaturated
fatty acid
elongation.
Posteriori
analysis
suggested
that their
expression
levels
were
bothaffects
decreased
by maternal
choline
Posteriori
analysis
suggested
that
their
expression
levels
were
both
decreased
by
maternal
supplementation during HF feeding (Acc1: HFCS versus the other three groups, p < 0.05; Elovl5: HFCS choline
supplementation
versus HFCO,
p = 0.01). during HF feeding (Acc1: HFCS versus the other three groups, p < 0.05; Elovl5:
HFCS
versus
HFCO,
p = 0.01).of lipid metabolism, including Ppara and Acox1 which mediate
Genes related
to other
pathways
Genes
related
to
other pathways
of lipid
metabolism,
Acox1
which mediate
β-oxidation of fatty acid catabolism,
Fatp1 which
helps
fatty acid including
transport, Ppara
Dgat1and
which
mediates
β-oxidation
of fatty
acid catabolism,
Fatp1 or
which
acidwith
transport,
Dgat1assembly
which mediates
the esterification
reaction
of triglyceride
synthesis,
Mttphelps
whichfatty
assists
lipoprotein
the
esterification
reaction
of
triglyceride
synthesis,
or
Mttp
which
assists
with
lipoprotein
assembly
were not differentially expressed due to HF feeding or maternal choline supplementation (p > 0.05)
were
not
differentially
expressed
due
to
HF
feeding
or
maternal
choline
supplementation
(p > 0.05)
(Figure 4a).
(Figureand
4a). ChREBP1 are transcription factors that upregulate lipogenesis. Maternal HF
SREBP-1c
SREBP-1c
and ChREBP1
are transcription
factors
that
upregulate
lipogenesis.
Maternal HF
feeding and choline supplementation
tended
to interact to affect
their
expression
(Figure
4b). Posteriori
and
tended
interact
affectNFCO
their group
expression
(Figure 4b).
analysis feeding
suggested
thatcholine
Srebp1csupplementation
mRNA levels were
lower to
in the
HFCStoversus
(p = 0.02),
Posteriori
analysis
suggested
that
Srebp1c
mRNA
levels
were
lower
in
the
HFCS
versus
NFCO
while there was no significant difference in its gene expression between the HFCO and NFCO groups group
(p =Chrebp1
0.02), while
there was noonly
significant
difference
in(pits= gene
between
HFCO and
(Figure 4b).
was upregulated
in the HFCO
group
0.03),expression
but not in the
HFCSthe
group
NFCO groups
(Figure
4b). Chrebp1
upregulated
only inand
thethe
HFCO
(p = 0.03),
but not in the
when compared
to NFCO.
Collectively,
bothwas
the decrease
in Srebp1c
lack group
of increase
in Chrebp1
HFCS
group
when
compared
to
NFCO.
Collectively,
both
the
decrease
in
Srebp1c
and
the lack of
mRNA abundance due to maternal choline supplementation may facilitate attenuation of hepatic
increase
in
Chrebp1
mRNA
abundance
due
to
maternal
choline
supplementation
may
facilitate
lipogenesis during HF feeding.
attenuation of hepatic lipogenesis during HF feeding.

Nutrients 2017, 9, 899

Nutrients 2017, 9, 899

9 of 15

9 of 15

Figure 4. Fetal liver mRNA abundance at E17.5. Experimental diets were fed to dams from 6 weeks
Figure 4. Fetal liver mRNA abundance at E17.5. Experimental diets were fed to dams from 6 weeks
before
timed-mating to gestational day 17.5. (a) Genes involved in lipid metabolism; (b) transcription
before timed-mating to gestational day 17.5. (a) Genes involved in lipid metabolism; (b) transcription
factors;
(c) genes
involved
in choline
metabolism.
mRNA
factors;
(c) genes
involved
in choline
metabolism.
mRNAlevels
levelswere
weremeasured
measured by
by real-time
real-time PCR.
PCR. Data
wereData
analyzed
using
the
general
linear
model.
Data
were
analyzed
using
the
general
linear
model.
were analyzed using the general linear model. Data were analyzed using the general linear
Posteriori
analysis
of
variance
(ANOVA)
followed
by
posthoc
Fisher’s
least
significant
difference
model. Posteriori analysis of variance (ANOVA) followed by posthoc Fisher's least significant(LSD)
D×S ≤ 0.2.
NFCO
bars):
n = 9; bars):
difference
(LSD)
analysis
groups
with p(solid
analysis
between
groups
wasbetween
conducted
withwas
pD×conducted
bars):
n = (solid
9; NFCS
(shaded
S ≤ 0.2. NFCO
NFCS
(shaded
bars):
n
=
6;
HFCO
(open
bars):
n
=
7;
HFCS
(hatched
bars):
n
=
6.
n
is
the
number
of two
n = 6; HFCO (open bars): n = 7; HFCS (hatched bars): n = 6. n is the number of dams. Data from
dams.
Data
from
two
fetuses
in
each
dam
were
pooled
and
included
in
the
analysis.
Values
are
mean
fetuses in each dam were pooled and included in the analysis. Values are mean ± standard error of mean
± standard
of indicate
mean (SEM);
different
indicate
p < 0.05
ns: pD, pS,
(SEM);
differenterror
letters
p < 0.05
in theletters
posthoc
analysis;
ns: pinD ,the
pS ,posthoc
and pD×analysis;
S , not significant. Acc:
and pD×S, not significant. Acc: acetyl-CoA carboxylase; Acox1: peroxisomal acyl-coenzyme A oxidase 1;
acetyl-CoA carboxylase; Acox1: peroxisomal acyl-coenzyme A oxidase 1; Bhmt: betaine-homocysteine
Bhmt: betaine-homocysteine S-methyltransferase; Chdh: choline dehydrogenase; Chrebp1:
S-methyltransferase; Chdh: choline dehydrogenase; Chrebp1: Carbohydrate-responsive element-binding
Carbohydrate-responsive element-binding protein; Dgat1: diacylglycerol O-acyltransferase 1; Elovl5:
protein; Dgat1: diacylglycerol O-acyltransferase 1; Elovl5: fatty acid elongase 5; Fasn: fatty acid
fatty acid elongase 5; Fasn: fatty acid synthase; Fatp1: fatty acid transport protein 1; Mttp: microsomal
synthase;
Fatp1: fatty
acid transport
Mttp: microsomal triglyceride
transfer protein;
Pcyt1a:
triglyceride
transfer
protein; protein
Pcyt1a: 1;choline-phosphate
cytidylyltransferase
A; Pemt:
choline-phosphate
cytidylyltransferase
A;
Pemt:
phosphatidylethanolamine
N-methyltransferase;
phosphatidylethanolamine N-methyltransferase; Ppara: Peroxisome proliferator-activated receptorPpara:
Peroxisome
proliferator-activated
receptorSrebp1:
alpha;Sterol
Scd1:regulatory
stearoyl-CoA
desaturase-1;
Srebp1:
alpha; Scd1:
stearoyl-CoA desaturase-1;
element-binding
protein
1; CO:Sterol
regulatory
protein 1; CO: D:
control;
choline
supplemented;
D: diet; HF:diet;
high-fat
control;element-binding
CS: choline supplemented;
diet; CS:
HF:
high-fat
diet; NF: normal-fat
S: diet;
supplementation.
NF: normal-fat
diet; S: supplementation.

3.3.3. HF Feeding and Maternal Choline Supplementation Altered Fetal Hepatic Choline Metabolism

3.3.3. HF Feeding and Maternal Choline Supplementation Altered Fetal Hepatic Choline Metabolism
We then examined choline metabolite concentrations in the fetal liver (Table 3). HF feeding led
We then examined choline metabolite concentrations in the fetal liver (Table 3). HF feeding led to
to 17% lower free choline content versus NF (pD = 0.05). Conversely, maternal choline
17% supplementation
lower free choline
content
0.05).
Conversely,
maternal choline
supplementation
D =
tended
to versus
increaseNF
(p(p
S =
0.07)
free
choline concentrations.
Maternal
choline
tended
to
increase
(p
=
0.07)
free
choline
concentrations.
Maternal
choline
supplementation
increased
supplementation Sincreased fetal liver betaine content by 80% (CS versus CO, p < 0.01), especially
in
fetal the
liver
betaine
content
by 80%
(CS
versus
CO, pthan
< 0.01),
especially
in the (p
HFCS
group
HFCS
group
which had
higher
betaine
content
the other
three groups
< 0.05).
Otherwhich
fetal had
liver
choline
metabolites
not altered
by HF feeding
or choline
higher
betaine
content
than were
the other
three groups
(p < 0.05).
Othersupplementation.
fetal liver choline metabolites were

not altered by HF feeding or choline supplementation.

Nutrients 2017, 9, 899

10 of 15

Table 3. Choline-derived metabolite concentrations in the fetal liver at gestational day 17.5 1 .
Metabolites (nmol/g Tissue)
Choline
Betaine
Methionine
Lysophosphatidylcholine
Glycerophosphocholine
Phosphocholine
Phosphatidylcholine
Sphingomyelin

NFCO

NFCS

HFCO

HFCS

p Value

(n = 9)

(n = 6)

(n = 7)

(n = 6)

D

S

D×S

172 ± 12
719 ± 89 a
139 ± 12
253 ± 28
633 ± 60
537 ± 54
22,006 ± 914
3707 ± 228

196 ± 13
1290 ± 102 b
158 ± 14
235 ± 33
735 ± 70
687 ± 62
21,511 ± 1055
3423 ± 263

144 ± 13
957 ± 103 a
134 ± 14
273 ± 32
610 ± 70
486 ± 62
21,515 ± 1055
3794± 263

169 ± 13
1740 ± 103 c
134 ± 14
177 ± 33
587 ± 69
629 ± 62
19,317 ± 1055
3474 ± 263

0.05
<0.01
0.3
0.6
0.2
0.02
0.2
0.8

0.07
<0.01
0.5
0.08
0.6
0.4
0.2
0.2

0.9
0.2
0.5
0.3
0.4
0.9
0.4
0.9

1

Experimental diets were fed to dams from 6 weeks before timed-mating to gestational day 17.5. n is the number
of fetuses. Livers of 6–9 fetuses from different dams (1 fetal liver/dam) were randomly chosen from each group
for quantification. Data were analyzed using the general linear model. Posteriori analysis of variance (ANOVA)
followed by posthoc Fisher’s least significant difference (LSD) analysis between groups was conducted with pD×S
≤ 0.2. Different letters: a, b, and c, indicate p < 0.05 in the posthoc analysis; Values represent means ± standard
error of mean (SEM). CO: control; CS: choline supplemented; D: diet; HF: high-fat diet; NF: normal-fat diet;
S: supplementation.

Lastly, we examined whether the expression of genes involved in choline metabolism was altered
by the different diets. Maternal HF feeding and choline supplementation interacted (pD×S = 0.05)
to affect the mRNA levels of Bhmt1 which mediates methyl group donation from betaine to
homocysteine. Bhmt1 expression was decreased by maternal choline supplementation during HF
feeding (70% decrease, HFCS versus HFCO, p = 0.03). Previous studies suggest that BHMT1 is
downregulated by S-adenosylmethionine which is derived from methionine, a reaction product of
BHMT1 [40]. Both the decrease in Bhmt1 expression and increase in betaine content in the HFCS group
suggest an enhanced methylation activity. Other genes involved in choline metabolism, including
Pemt, Chdh, and Pcyt1a, were not altered by HF feeding or choline supplementation.
4. Discussion
In the current study, we investigated the influence of maternal choline supplementation on fetal
adiposity and hepatic lipid metabolism at E17.5 (late gestation) in mice fed a HF diet to induce maternal
obesity. We have found that HF feeding increased fetal adiposity and hepatic fat accumulation, whereas
maternal choline supplementation attenuated these abnormalities and downregulated the expression
of lipogenic genes in the fetal liver.
It is well established that choline deficiency results in steatosis, whereas choline and betaine
supplementation improves non-alcoholic fatty liver disease (NAFLD) in adult animals [24]. We report
here for the first time that maternal choline supplementation before and during gestation prevented
excess adiposity and hepatic triglyceride over-accumulation in fetuses from HF-fed mouse dams. These
results are consistent with the proposed model where choline influences macronutrient metabolism
and facilitates the maintenance of metabolic homeostasis [41], especially under the condition of an
environmental challenge (e.g., HF feeding).
In the current model of maternal HF feeding, we observed higher pre-pregnancy weight gain
and impaired glucose tolerance of dams at gestation day 15.5, which resembles GDM resulting from
maternal obesity in humans. Consistent with a previous report, fetal weight was not significantly
different between the HF and NF groups at E17.5 [10]. However, similar to the previous study [10],
the HFCO fetuses not only had higher percent total body fat, but also had higher triglyceride
concentrations in the liver versus NFCO. The mouse fetus acquires fat predominantly from maternal
transport but can also conduct de novo lipogenesis [9,42]. Although fat acquisition accelerates at late
gestation, the mouse fetus contains less than 10% of body weight as fat at birth. Nevertheless, adiposity
at birth is a good indicator of adiposity and glucose intolerance in adulthood [1]. As such, preventing
excess body fat accumulation at term may have positive implications for metabolic balance throughout
the life-course. In this study, maternal choline supplementation seems to be an effective way to prevent
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excess adiposity, since the HFCS fetus had comparable whole body adiposity and hepatic fat content
to NFCO.
The potential mechanism through which maternal choline supplementation helps normalize
fetal fat metabolism may be multi-faceted. Maternal choline supplementation improved fetal choline
status as was demonstrated by the higher betaine concentrations and the trend of higher free choline
concentrations in fetal livers in the present study. Increasing choline availability helps maintain
integrity of cellular membranes, provide structural materials for lipoproteins, provide ligands (PPAR-α,
LRH-1) or suppressors of transcription factors (SREBP-1c) that influence lipid metabolism [15–17],
and supply methyl groups for epigenetic control of lipid metabolic genes of the fetus [22,41,43].
Maternal choline supplementation may also affect maternal lipid metabolism, thereby altering placental
uptake and transport of lipids to the fetus. However, the current study suggested that maternal choline
supplementation increased lipid concentrations in maternal circulation, which was not consistent with
the lower lipid accretion of the HFCS versus the HFCO fetuses. Examination of the placenta will
provide more insights into the regulation of lipid transport to the fetus in response to HF feeding and
choline supplementation and help discern the discrepancy.
We explored the expression of genes related to fatty acid synthesis, esterification, degradation,
transport, and assembling into lipoprotein in the fetal liver. Downregulation of certain lipogenic genes
including Fasn, Scd1, and Acc2 in the fetal liver seemed to be a common response to maternal HF
feeding regardless of choline exposure. However, these observations directly contrasted with what was
found in studies of adult mice, in which HF feeding increased both Fasn and Scd1 expression [44,45].
These inconsistencies may be related to the adjustment in maternal transport of lipids or differential
regulation of the acquired fat by the fetal liver, which requires further investigation. We further
observed that maternal choline supplementation in HF dams decreased expression of other fatty acid
synthesizing genes, including Acc1, Elovl5, and Fads1. The additional decrease in de novo lipogenic
gene expression in the HFCS versus HFCO fetuses may further diminish fatty acid synthesis, thereby
compensating for the increased influx of lipids from the HF dams.
The main mechanism by which choline exerts its impact on lipogenesis remains to be elucidated.
One potential mediator is SREBP-1c, a transcription factor that upregulates a series of lipogenic
genes including those we examined. The HFCS group had lower Srebp1c expression compared
with the NFCO group whereas the HFCO group did not downregulate the expression of this gene.
Maintenance of cellular membrane PC is necessary to prevent SREBP-1c from translocating to the
nucleus and functioning as a transcription factor [17]. Although PC content in the fetal liver was not
significantly different among the groups, maternal HF feeding decreased free choline content of fetal
livers, which could be a result of increased use of choline, possibly to synthesize PC. Maternal choline
supplementation tended to increase fetal hepatic free choline status thereby counteracting the effect of
HF feeding.
ChREBP1, a transcription factor that gets activated by hyperglycemia, also upregulates
lipogenesis [46]. Chrebp1 expression increased in the HFCO fetal liver but not in the HFCS fetal
liver when compared to NFCO animals. This may also contribute to the observed lower lipogenic
gene expression in the HFCS group. However, since we do not have data about fetal glucose levels,
we cannot conclude that better fetal glycemic control in the HFCS group prevented the elevation in
Chrebp1 expression.
The decrease in de novo lipogenic gene expression does not preclude other possible mechanisms
by which choline regulates fetal fat metabolism. Therefore, we examined the expression of fetal
hepatic Mttp which participates in lipoprotein assembly, as well as Ppara and Acox1 which participate
in lipid catabolism, yet did not find significant differences among the four groups. A previous
study [47] suggested that choline deficiency exacerbated fatty liver in HF fed mice but improved
glucose tolerance. The authors speculated that choline deficiency decreased the use of diacylglycerol
for phosphatidylcholine synthesis, thereby sparing hepatic diacylglycerol for FFA esterification.
The increased use of FFAs for esterification reduced the levels of circulating FFAs, a known risk
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factor for impaired glucose tolerance [47]. However, we did not find any changes in expression of
Dgat1, which mediates the last step of esterification to form triglycerides, among the groups either.
Since we did not retrieve blood from the fetuses, we could not quantify and determine whether FFAs
or lipoproteins were lower in the circulation of HFCS fetuses compared with HFCO. It should be noted
that the difference in fetal fat accumulation could also be a result of differential maternal transport
of lipids. Although the triglyceride concentrations in maternal circulation were higher in the HFCS
versus HFCO group, the HFCS fetuses had lower adiposity. Whether it was due to reduced placental
lipid uptake or transport remains to be discerned.
Another significant difference between the HFCS and HFCO fetal livers relates to their betaine
content, suggesting that the epigenetic regulation of hepatic genes could be affected by the different
availability of this methyl donor for DNA and histone methylation. The lower expression of Bhmt1 in
the HFCS group versus the NFCO group may also indicate an ample supply of betaine as the substrate
for methyl group donation and generation of S-adenosylmethionine, because S-adenosylmethionine
provides feedback inhibition which downregulates BHMT [40]. Supplementation of betaine to
the maternal diet has been shown to enhance DNA methylation of genes involved in cholesterol
metabolism in neonatal piglets [26]. The genes that we observed to be downregulated in the HFCS
group, such as Srebp1c and Fads1, have also been reported to be regulated by DNA methylation in
other studies [48,49]. Further study is needed to quantify DNA methylation of the lipogenic genes to
confirm the role of epigenetics in controlling their expression in the current model.
Our study provides supportive evidence that maternal choline supplementation normalizes fetal
adiposity and reduces lipogenic gene expression in HF fed mice at term. Although we do not have
corresponding protein levels for the genes, based on previous studies [50,51], mRNA abundance
assessed by real-time PCR seems to be a sensitive method to detect subtle transcriptional changes
that are induced by dietary factors. The consistent decreases in the expression of a group of lipogenic
genes, in combination with the phenotypic difference in fat content, further strengthen our mechanistic
model. Future studies should be directed in further delineating mechanisms by which maternal choline
supplementation modulates fetal response to maternal HF feeding.
5. Conclusions
In conclusion, during HF feeding, maternal choline supplementation prevents excess adiposity
and hepatic triglyceride overload in mouse fetuses. Downregulation of lipogenic gene expression in
the fetal liver is a possible mechanism by which fetal adiposity is attenuated in the HFCS animals.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/9/8/899/s1,
Table S1: Primers used for real-time PCR.
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